Lanciprol (Lansoprazole)

Lansoprazole belongs to the proton pump inhibitor class. It binds irreversibly to the H⁺/K⁺‑ATPase enzyme on gastric parietal cells, blocking the final step of acid secretion. This results in a sustained reduction of gastric acidity, allowing damaged mucosa to heal and reducing symptoms caused by excess acid.

The appropriate dose of Lanciprol is determined by the prescribing healthcare professional based on the specific condition, severity, and patient characteristics. Dosage recommendations are provided in the product label, and the prescriber will tailor the regimen to each individual’s therapeutic needs.

Safety data for lansoprazole in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers will evaluate the risk‑benefit profile before prescribing it to pregnant or nursing patients.

To request Lanciprol, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Lanciprol (lansoprazole) and omeprazole belong to the same drug class and share a similar mechanism of action. Differences lie in pharmacokinetic profiles; lansoprazole often achieves a slightly faster onset of acid suppression and may have a marginally longer half‑life, which can influence dosing frequency and individual patient response.

Lanciprol tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original packaging to protect from moisture and light. Do not store in bathrooms or near heat sources, and keep out of reach of children.

Lanciprol is taken orally, usually as a whole tablet with a glass of water. It is commonly recommended to take the dose before a meal, often in the morning, but the exact timing should follow the prescriber’s instructions to achieve optimal acid control.

Serious but rare adverse events include Clostridioides difficile‑associated colitis, interstitial nephritis, severe liver injury, and hypersensitivity reactions such as Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience persistent diarrhea, rash, jaundice, or unexplained kidney‑related symptoms.

Lanciprol is contraindicated in individuals with known hypersensitivity to lansoprazole or any component of the formulation. Caution is advised for patients with severe liver disease, those taking certain interacting medications such as clopidogrel, and patients with a history of osteoporosis when long‑term therapy is considered.